Post by
beechguy on Sep 17, 2014 10:50am
Excerpt from article
This is not a fly by night analyst!
Bioniche could be the most undervalued stock currently trading on the market, and I think certainly the most undervalued biotech stock. Bioniche is rushing to obtain FDA approval, which could happen as early as next year, thanks to the fast-track route the FDA has given the green light for. There is a critical medical need for Bioniche's technology in a $1 billion market virtually free of real competition, which opens the door for massive revenue growth, while the sound financials limits downside risk. Overall, today's $0.20 share price appears to me as an excellent entry point for a genuine 10-bagger opportunity. One thing's for sure; opportunities of this magnitude are very rare.